Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
about
Non-canonical signaling mode of the epidermal growth factor receptor familyVersican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapyPGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells.Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.Nuclear trafficking of the epidermal growth factor receptor family membrane proteins.YM155 induces EGFR suppression in pancreatic cancer cells.HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathwayPharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locationsActivation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor familyNuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications.Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review).Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors.KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.Array-based pharmacogenomics of molecular-targeted therapies in oncology.Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.Nuclear EGFR as a molecular target in cancer.The Mysterious Ways of ErbB2/HER2 TraffickingEmerging mAbs for the treatment of esophagogastric cancer.Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery SystemLapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase.The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.Capturing drug responses by quantitative promoter activity profiling.Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.How to overcome resistance to therapy?Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors.Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.Lapatinib ameliorates experimental arthritis in rats.EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact.
P2860
Q26773754-298DD05E-1C56-45EF-B290-1C4141823547Q28477876-816FB3B9-E818-47B6-83A0-8C736DEA4D97Q33761715-BCFCF912-9C80-458D-86CC-D100F02B36ABQ33829760-F3B1CDD0-6FAE-47FD-83A5-4375D36C2A91Q33998459-6B51FCCC-8112-40DE-8AAC-2FC58C36DE3DQ34313903-85C9BDBC-7C79-4B0F-92AE-102A4805F09FQ34942996-252A4E3D-75AD-40C7-BE00-DF56231CBE23Q35185574-A983EC83-0AFE-4A9A-8D6D-6552D5B6D464Q35374477-12CFDFF5-0C6F-4A4E-82BC-78FF513ACD15Q35535547-1BD9C7C8-E70B-4821-BF92-0DB5E3A5C56AQ35783451-BA6AC914-8AD5-43E1-A419-695668D4AA07Q35831012-D74ED655-7A07-4DD2-8A3F-83665CFF9F97Q36062158-EF5B97D2-1B2B-4ACE-8803-51CEE5960A9DQ36113481-35261DF5-C228-4951-90CA-A43AFC908D7AQ36162605-E31B3D3E-D1FC-48BD-AC67-51EA49F9135AQ36798851-A4A6D347-5692-4F00-BA1D-D242D220FAA7Q37332545-F7FBE620-771A-4A39-B7AA-7591047DCE5AQ37361549-FB975F3D-7905-4432-900E-DD133025CB4CQ37567784-0534E3CE-7842-4495-A017-D798843CFA77Q37622619-CB061F85-45F9-49D9-97C1-FB92186AB3C7Q37709450-3E1255BA-DFE6-4DA8-A6C3-98E66B7E07BDQ37976288-E141C0DB-FF15-45AB-90C1-43B57A15A534Q38090584-A2C26F1F-1074-48EB-8C7A-0E520302E1B6Q38119635-B524C360-4CC0-45F0-811A-DA465EE1ABD5Q38237727-7DAC5BE9-1D7D-45F1-A37A-EDCA53CF87BEQ38284597-834E932F-2751-4295-8D20-79CBF269D961Q38634426-835E063F-8911-438B-9CB3-3ECF83E50FAFQ38812867-A35E45F6-C79C-4E88-8254-589E2F02B539Q39122676-979E9A3D-FCBE-4C88-967F-76B048BE6391Q39180988-9569F918-A753-4FE2-9F7A-C494FAB8AB6DQ39422598-B991956E-8ECE-469A-9493-C3940B39E70AQ39756394-08FCA894-8199-4986-BBA4-884B70577C59Q41452420-91FB2132-DB1E-4CEA-96CC-B78BB8330780Q42094716-B8F17845-73AC-4400-9B3E-C5D4DB4F0228Q42211322-4F469AE2-374A-429C-8CA2-3841AC5FD8C1Q46225923-1A8860B4-7A78-42DF-A029-34A87C75CA8AQ51108993-83609AC1-EBE2-417B-86E8-BA78FF77EB83Q53284577-63877867-0907-4F57-906B-30D6FD6E97BA
P2860
Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lapatinib, a dual EGFR and HER ...... ranslocation of EGFR and HER2.
@ast
Lapatinib, a dual EGFR and HER ...... ranslocation of EGFR and HER2.
@en
type
label
Lapatinib, a dual EGFR and HER ...... ranslocation of EGFR and HER2.
@ast
Lapatinib, a dual EGFR and HER ...... ranslocation of EGFR and HER2.
@en
prefLabel
Lapatinib, a dual EGFR and HER ...... ranslocation of EGFR and HER2.
@ast
Lapatinib, a dual EGFR and HER ...... ranslocation of EGFR and HER2.
@en
P2093
P2860
P1433
P1476
Lapatinib, a dual EGFR and HER ...... ranslocation of EGFR and HER2.
@en
P2093
Do-Youn Oh
Hwang-Phill Kim
Hyung-Seok Hur
Jin-Won Kim
Jinah Park
Ju-Hee Lee
Sae-Won Han
Seock-Ah Im
Tae-You Kim
Young-Kwang Yoon
P2860
P356
10.1371/JOURNAL.PONE.0005933
P407
P577
2009-06-16T00:00:00Z